Related Experiment Video
Updated: May 15, 2026
06:17
3D Human Myocardial Tissue Generation Using Melt Electrospinning Writing of Polycaprolactone Scaffolds and hiPSC-Derived Cardiac Cells
Published on: March 28, 2025
Prevascularized microtemplated fibrin scaffolds for cardiac tissue engineering applications
Kassandra S Thomson1, F Steven Korte, Cecilia M Giachelli
1Department of Bioengineering, University of Washington, Seattle, WA 98195, USA.
Tissue Engineering. Part A
|January 16, 2013
Summary
This study introduces a novel fibrin scaffold for cardiac tissue engineering, improving cell survival and integration after myocardial infarction. The engineered scaffold enhances cell retention and promotes host-graft integration for better treatment outcomes.
Area of Science:
- Biomaterials Science
- Cardiovascular Research
- Tissue Engineering
Background:
- Myocardial infarction (MI) leads to significant cell loss and myocardial damage.
- Current cell-based therapies face challenges with transplanted cell survival and host tissue integration.
- Existing scaffolds improve cell retention but often fail to enhance host-graft integration or exhibit limited biodegradation.
Purpose of the Study:
- To develop and characterize a novel, high-density microtemplated fibrin scaffold for cardiac tissue engineering.
- To improve cell retention and promote integration of grafted tissue with the host post-myocardial infarction.
- To mimic native cardiac tissue structure and cellular composition using a tri-cell mixture (cardiomyocytes, endothelial cells, fibroblasts).
Main Methods:
- Fabrication of fibrin scaffolds with uniform microchannels (60 μm) and microporous networks (27 μm).
- Tuning mechanical stiffness to match native cardiac tissue (70-90 kPa).
- Controlled degradation using Factor XIII (FXIII) and/or aprotinin; evaluation of cell survival, organization, and extracellular matrix deposition in vitro and in vivo.
Main Results:
- Scaffolds treated with FXIII and/or aprotinin demonstrated significantly slowed degradation compared to unmodified scaffolds.
- In vitro studies showed supported seeded cell survival, organization, and extracellular matrix deposition, including EC-lined lumen formation.
- In vivo, while unmodified and aprotinin scaffolds degraded rapidly, FXIII-treated scaffolds showed some retention, indicating potential for improved integration.
Conclusions:
- The developed microtemplated fibrin scaffolds are designed to enhance graft cell survival and organization.
- Controlled degradation and structural properties promote better integration with host cardiac tissue.
- This approach holds promise for improving cell-based therapies for myocardial infarction treatment.
